In a recent survey, 89% of clinical adjudication users agreed clinical adjudication provides value to clinical trials.
| This week's Fierce Drug Delivery is brought to you by Bioclinica.
Trouble viewing? Click here.
|
| | Tuesday, November 2, 2021 | 1pm ET / 10am PT | |
|
|
| | | In a recent survey, 89% of clinical adjudication users agreed clinical adjudication provides value to clinical trials. Why? Because using unbiased experts to evaluate a drug or device against predetermined criteria helps determine patient safety and clinical efficacy. Join two Bioclinica experts for a discussion of these and other survey results to understand how they could impact your studies. |
|---|
| |
|
|
| | | In the webinar, we will discuss: The survey findings on the role of clinical adjudication in clinical trials The top three hurdles in using clinical adjudication for clinical trials The two most valuable services a clinical adjudication partner can provide Several considerations to evaluate when selecting a clinical adjudication partner for your next trial |
|---|
| |
|
|
| | You are currently subscribed as newsletter@newslettercollector.com
If you no longer wish to receive promotions from Fierce LifeSciences, simply unsubscribe.
Refer to our Privacy Policy.
Fierce LifeSciences is a division of Questex LLC.
685 3rd Ave 21st Floor New York, NY 10017
© 2021 Questex LLC. All Rights Reserved.
Reproduction in whole or in part is prohibited without written permission. | |
|
|
